Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$480K Buy
1,326
+297
+29% +$102K 0.01% 382
2026
Q1
$362K Buy
1,029
+8
+0.8% +$2.85K 0.01% 405
2025
Q4
$334K Sell
1,021
-58
-5% -$18.4K 0.01% 392
2025
Q3
$321K Buy
1,079
+13
+1% +$3.77K 0.01% 400
2025
Q2
$298K Buy
1,066
+147
+16% +$41.6K 0.01% 372
2025
Q1
$286K Buy
919
+100
+12% +$29.5K 0.01% 358
2024
Q4
$214K Buy
+819
New +$243K 0.01% 412
2020
Q4
Sell
-98
Closed -$25K 133
2020
Q3
$25K Buy
+98
New +$24.3K 0.01% 289
2020
Q1
Sell
-103
Closed -$24.4K 707
2019
Q4
$24.4K Sell
103
-67
-39% -$14.8K 0.01% 378
2019
Q3
$33.4K Buy
+170
New +$32.6K 0.01% 294
2019
Q2
Sell
-59
Closed -$10.2K 142
2019
Q1
$10.2K Buy
+59
New +$11.3K ﹤0.01% 403

Other funds holding AMGN

Advisory Alpha's AMGN Position: Q2 2026 in Review

Advisory Alpha increased its Amgen (AMGN) stake by 29% in Q2 2026, buying an estimated $102K and bringing the position to 1,326 shares worth $480K. The position accounts for 0.01% of the portfolio, ranked #382.

Advisory Alpha first reported a position in AMGN in Q1 2019 and has held it in 11 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Advisory Alpha held 1,326 shares of Amgen worth $480K as of Q2 2026.
  • Advisory Alpha bought 297 Amgen shares in Q2 2026, an estimated $102K.
  • Amgen made up 0.01% of Advisory Alpha's portfolio in Q2 2026, its #382 holding.
  • Advisory Alpha first reported a position in Amgen in Q1 2019 and has held it in 11 quarters since.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Advisory Alpha's 13F filing for Q2 2026, filed 11 Aug 2026.